Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Growth Hormone Deficiency

Interventions

DRUG: ALRN-5281 0.015 mg/kg
DRUG: ALRN-5281 0.05 mg/kg
DRUG: ALRN-5281 0.15 mg/kg
DRUG: Placebo 0.015 mg/kg
DRUG: Placebo 0.05mg/kg
DRUG: Placebo 0.15mg/kg

Sponsor

Aileron Therapeutics, Inc.